glp-1 compound news FDA Intensifies Crackdown on Compounding Despite FDA ruling, compounded GLP-1s

Risk factors associated with NAION can include diabetes, hypertension, sleep apnea, vascular disease, and other conditions affecting blood circulation and optic nerve health

[DOI] [PubMed] [Google Scholar] 59.Margulies K.B., Hernandez A.F., Redfield M.M., Givertz M.M., Oliveira G.H., Cole R., Mann D.L., Whellan D.J., Kiernan M.S., Felker G.M., et al

In its fourth-quarter earnings call, Novo Nordisk estimated that about 50 million Americans with obesity now have access to Wegovy

Search strategy A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar was conducted for studies published up to May 2025, identifying 132 articles

When the scale stalls, the rest of the timeline often shows what is changing even if the number did not move

however, most phase III clinical studies are of insufficient duration and do not include enough study participants to effectively gauge long-term safety